Cronos Group Inc banner

Cronos Group Inc
NASDAQ:CRON

Watchlist Manager
Cronos Group Inc Logo
Cronos Group Inc
NASDAQ:CRON
Watchlist
Price: 2.48 USD 1.64%
Market Cap: $947.4m

Multiples-Based Value

The Multiples-Based Value of one CRON stock under the Base Case scenario is hidden USD. Compared to the current market price of 2.48 USD, Cronos Group Inc is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRON Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

CRON Competitors Multiples
Cronos Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cronos Group Inc
NASDAQ:CRON
1.3B USD 6.5 -100.8 -299.9 -8
US
Eli Lilly and Co
NYSE:LLY
837.7B USD 13.3 41.8 28.3 30.2
US
Johnson & Johnson
NYSE:JNJ
583.9B USD 6.2 21.8 15.2 18.6
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
UK
AstraZeneca PLC
LSE:AZN
227.8B GBP 5.2 29.9 16.5 23.3
US
Merck & Co Inc
NYSE:MRK
292.3B USD 4.6 16.3 10.1 12.3
CH
Novartis AG
SIX:NOVN
229.9B CHF 5.3 21.5 13.3 17.1
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
US
Pfizer Inc
NYSE:PFE
157.9B USD 2.5 20.4 7.8 10.4
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.1 7.5 8.8
US
Bristol-Myers Squibb Co
NYSE:BMY
120.2B USD 2.5 17.2 7.2 8.9
P/E Multiple
Earnings Growth PEG
CA
Cronos Group Inc
NASDAQ:CRON
Average P/E: 22.1
Negative Multiple: -100.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.9
26%
1.1
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
CH
Novartis AG
SIX:NOVN
21.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.4
22%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
1%
10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Cronos Group Inc
NASDAQ:CRON
Average EV/EBITDA: 49.3
Negative Multiple: -299.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.3
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.5
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
3%
3.4
CH
Novartis AG
SIX:NOVN
13.3
5%
2.7
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
-9%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.5
1%
7.5
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Cronos Group Inc
NASDAQ:CRON
Average EV/EBIT: 108.4
Negative Multiple: -8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.2
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.3
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.3
6%
2
CH
Novartis AG
SIX:NOVN
17.1
9%
1.9
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
-4%
N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.8
2%
4.4
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett